Diagnostic value of osteopontin in ovarian cancer: Meta-analysis and systematic review

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Hu, Zhi De ^a,b   Wei, Ting Ting ^a   Yang, Min ^a   Ma, Ning ^a   Tang, Qing Qin ^a   Qin, Bao Dong ^a   Fu, Hai Tao ^a   Zhong, Ren Qian ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; OSTEOPONTIN; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HUMAN; META ANALYSIS; OVARY CANCER; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; FEMALE; OVARY TUMOR; PATHOPHYSIOLOGY; PHYSIOLOGY;

FEMALE; HUMANS; OSTEOPONTIN; OVARIAN NEOPLASMS;

EID: 84929335527     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0126444     Document Type: Article

References (40)

1. Siegel R, Ma J, Zou ZJemal A Cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 9-29. doi: 10.3322/caac.21208 PMID: 24399786
2. Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat. 2014; 46: 109-123. doi: 10.4143/crt.2014.46.2.109 PMID: 24851102
3. Chen W, Zheng R, Zhang S, Zhao P, Zeng H, Zou X, et al. Annual report on status of cancer in China, 2010. Chin J Cancer Res. 2014; 26: 48-58. doi: 10.3978/j.issn.1000-9604.2014.01.08 PMID: 24653626
4. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380: 2095-2128. doi: 10.1016/S0140-6736(12)61728-0 PMID: 23245604
5. Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014; 384: 1376-1388. doi: 10.1016/S0140-6736(13)62146-7 PMID: 24767708
6. Baldwin LA, Huang B, Miller RW, Tucker T, Goodrich ST, Podzielinski I, et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012; 120: 612-618. PMID: 22914471
7. Smith LH. Early clinical detection of ovarian cancer: a review of the evidence. Expert Rev Anticancer Ther. 2006; 6: 1045-1052. PMID: 16831076
8. Bast RC Jr, Xu FJ, Yu YH, Barnhill S, Zhang Z, Mills GB. CA 125: the past and the future. Int J Biol Markers. 1998; 13: 179-187. PMID: 10228898
9. Medeiros LR, Rosa DD, da Rosa MIBozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009; 142: 99-105. doi: 10.1016/j.ejogrb.2008.08.011 PMID: 18995946
10. Ahmed M, Behera R, Chakraborty G, Jain S, Kumar V, Sharma P, et al. Osteopontin: a potentially important therapeutic target in cancer. Expert Opin Ther Targets. 2011; 15: 1113-1126. doi: 10.1517/14728222.2011.594438 PMID: 21718227
11. Rittling SR. Osteopontin in macrophage function. Expert Rev Mol Med. 2011; 13: e15. doi: 10.1017/S1462399411001839 PMID: 21545755
12. Hu ZD, Liu XF, Liu XC, Ding CM, Hu CJ. Diagnostic accuracy of osteopontin for malignant pleural mesothelioma: a systematic review and meta-analysis. Clin Chim Acta. 2014; 433: 44-48. doi: 10.1016/j.cca.2014.02.024 PMID: 24607327
13. Cheng J, Wang W, Sun C, Li M, Wang BL. Y Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol. 2014; 48: 806-814. doi: 10.1097/MCG.0000000000000018 PMID: 24247813
14. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res. 2006; 12: 3337-3343. PMID: 16740755
15. Wang YD, Chen H, Liu HQ, Hao M. Correlation between ovarian neoplasm and serum levels of osteopontin: a meta-analysis. Tumour Biol. 2014; 35: 11799-11808. doi: 10.1007/s13277-014-2314-1 PMID: 25192720
16. Weber GF, Lett GS, Haubein NC. Categorical meta-analysis of Osteopontin as a clinical cancer marker. Oncol Rep. 2011; 25: 433-441. doi: 10.3892/or.2010.1106 PMID: 21165579
17. Moher D, Liberati A, Tetzlaff J, Altman DG. Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009; 151: 264-269, W264. PMID: 19622511
18. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011; 155: 529-536. doi: 10.7326/0003-4819-155-8-201110180-00009 PMID: 22007046
19. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005; 58: 982-990. PMID: 16168343
20. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol. 2005; 58: 882-893. PMID: 16085191
21. B D. Midas: computational and graphical routines for meta-analytical integration of diagnostic accuracy studies in Stata. 2007.
22. Kim JH, Skates SJ, Uede T, Wong KK, Schorge JO, Feltmate CM, et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA. 2002; 287: 1671-1679. PMID: 11926891
23. Mor G, Visintin I, Lai Y, Zhao H, Schwartz P, Rutherford T, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A. 2005; 102: 7677-7682. PMID: 15890779
24. Nakae M, Iwamoto I, Fujino T, Maehata Y, Togami S, Yoshinaga M, et al. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. J Obstet Gynaecol Res. 2006; 32: 309-314. PMID: 16764622
25. Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, et al. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res. 2007; 13: 458-466. PMID: 17255266
26. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008; 108: 402-408. PMID: 18061248
27. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008; 14: 1065-1072. doi: 10.1158/1078-0432.CCR-07-1569 PMID: 18258665
28. Fredriksson S, Horecka J, Brustugun OT, Schlingemann J, Koong AC, Tibshirani R, et al. Multiplexed proximity ligation assays to profile putative plasma biomarkers relevant to pancreatic and ovarian cancer. Clin Chem. 2008; 54: 582-589. doi: 10.1373/clinchem.2007.093195 PMID: 18171715
29. Vrzalova J, Prazakova M, Novotny Z, Topolcan O, Casova MHolubec L Jr. Test of ovarian cancer multiplex xMAP technology panel. Anticancer Res. 2009; 29: 573-576. PMID: 19331205
30. Lu D, Kuhn E, Bristow RE, Giuntoli RL 2nd, Kjaer SK, Shih Ie M, et al. Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol. 2011; 122: 560-566. doi: 10.1016/j.ygyno.2011.05.039 PMID: 21704359
31. He G, Holcroft CA, Beauchamp MC, Yasmeen A, Ferenczy A, Kendall-Dupont J, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can. 2012; 34: 567-574. PMID: 22673173
32. Bandiera E, Zanotti L, Fabricio AS, Bucca E, Squarcina E, Romani C, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin-related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2013; 51: 1815-1824. doi: 10.1515/cclm-2013-0151 PMID: 24013103
33. Moszynski R, Szubert S, Szpurek D, Michalak S, Sajdak S. Role of osteopontin in differential diagnosis of ovarian tumors. J Obstet Gynaecol Res. 2013; 39: 1518-1525. doi: 10.1111/jog.12097 PMID: 23875677
34. Milivojevic M, Boskovic V, Atanackovic J, Milicevic S, Razic S, Kotlica BK. Evaluation of osteopontin and CA125 in detection of epithelial ovarian carcinoma. Eur J Gynaecol Oncol. 2013; 34: 83-85. PMID: 23590008
35. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr,Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008; 27: 157-172; discussion 207-112. PMID: 17569110
36. Whiting P, Rutjes AW, Reitsma JB, Glas AS, Bossuyt PM, Kleijnen J. Sources of variation and bias in studies of diagnostic accuracy: a systematic review. Ann Intern Med. 2004; 140: 189-202. PMID: 14757617
37. Moons KG, de Groot JA, Linnet K, Reitsma JB, Bossuyt PM. Quantifying the added value of a diagnostic test or marker. Clin Chem. 2012; 58: 1408-1417. PMID: 22952348
38. Schmidt RL, Factor RE. Understanding sources of bias in diagnostic accuracy studies. Arch Pathol Lab Med. 2013; 137: 558-565. doi: 10.5858/arpa.2012-0198-RA PMID: 23544945
39. Rutjes AW, Reitsma JB, Vandenbroucke JP, Glas AS, Bossuyt PM. Case-control and two-gate designs in diagnostic accuracy studies. Clin Chem. 2005; 51: 1335-1341. PMID: 15961549
40. de Groot JA, Bossuyt PM, Reitsma JB, Rutjes AW, Dendukuri N, Janssen KJ, et al. Verification problems in diagnostic accuracy studies: consequences and solutions. BMJ. 2011; 343: d4770. doi: 10.1136/bmj.d4770 PMID: 21810869